Recent approvals from Sarepta, Bluebird Bio, and PTC Therapeutics, and news of expanding CNS pipelines have highlighted the popular interest in the next-generation of neurological gene therapies, so at the 5th Gene Therapy for Neurological Disorders Summit attendees were helped to propel their selves into the next wave of innovation.

This meeting helped attendees to overcome Discovery, Preclinical and Clinical Development, and regulatory challenges, from capsid engineering to preclinical model selection, immunogenicity, drug delivery, and regulation. The comprehensive 3-day discussion was full of need-to-know and practical insights. 

Now that the neurological gene therapy field has been given a renewed sense of direction, this summit gave attendees the opportunity to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders.